Tolerance induction using the Malmö treatment model 1982-1995.

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Patients with hemophilia who develop inhibitors face treatment challenges.
• Inducing immune tolerance is the primary goal for managing hemophilia patients with inhibitors.

Purpose of the Study:

• To summarize the experience of the Malmö centre in inducing immune tolerance in hemophilia patients with inhibitors using the Malmö Treatment Model.
• To evaluate the efficacy and success factors of this specific tolerance induction protocol.

Main Methods:

• The Malmö Treatment Model involves immunoadsorption (if needed), inhibitor neutralization, factor concentrate replacement, intravenous and oral cyclophosphamide, and daily intravenous gammaglobulin.
• The protocol was applied to 23 patients (16 hemophilia A, 7 hemophilia B) with inhibitors, with 36 total tolerance induction attempts.
• Key factors for success were analyzed, including inhibitor titre, historical peak titre, interval since last replacement therapy, and inflammatory state.

Main Results:

• Immune tolerance was achieved in 10 out of 16 hemophilia A patients (62.5%) and 6 out of 7 hemophilia B patients (86%).
• Success was more likely in patients with low inhibitor titres, lower historical peak titres, longer intervals since previous replacement therapy, and absence of inflammation.
• Successful tolerance induction was achieved within 3-4 weeks, a faster outcome compared to high-dose regimens.

Conclusions:

• The Malmö Treatment Model is an effective strategy for inducing immune tolerance in hemophilia patients with inhibitors.
• Patient-specific factors significantly influence the success rate of tolerance induction.
• This protocol offers a potentially faster route to tolerance compared to traditional high-dose approaches.